Natural products as potential human ether-A-Go-Go-related gene channel inhibitors - Screening of plant-derived alkaloids

Planta Medica

Volumn 80, Issue 8-9, 2014, Pages 740-746

  Schramm, Anja ^a   Saxena, Priyanka ^b   Chlebek, Jakub ^c   Cahlíková, Lucie ^c   Baburin, Igor ^b   Hering, Steffen ^b   Hamburger, Matthias ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF VIENNA   (Austria)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

hERG channel inhibition; in vitro library screening; natural products; plant derived alkaloids; Xenopus oocyte assay

Indexed keywords

8 OXOBERBERINE; ALKALOID DERIVATIVE; AMIODARONE; ARGEMONINE; BOLDINE; BULBOCAPNINE; CALIFORNIDINE; CHELIDONINE; CISAPRIDE; CORYNOLIN; EPHEDRINE; ESCHSCHOLTZINE; GALANTAMINE; HARMINE; INDIRUBIN; N METHYLLAUROTETANINE; NATURAL PRODUCT; NEOCARYACHINE; PAPAVERINE; POTASSIUM CHANNEL HERG; PROTOBERBERINE DERIVATIVE; PROTOPINE; RESERPINE; RETICULINE; ROTICHROM; SPARTEINE; TRYPTANTHRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASICINE; VASICINONE; YOHIMBINE; ALKALOID; BERBERINE DERIVATIVE; BIOLOGICAL PRODUCT; KCNH1 PROTEIN, HUMAN; POTASSIUM CHANNEL BLOCKING AGENT; PROTOBERBERINE;

ANIMAL CELL; ARTICLE; ASSAY; CONTROLLED STUDY; DRUG SCREENING; FEMALE; IN VITRO STUDY; NONHUMAN; RISK; ACTION POTENTIAL; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HUMAN; IC50; OOCYTE; PATCH CLAMP TECHNIQUE; XENOPUS LAEVIS;

ACTION POTENTIALS; ALKALOIDS; ANIMALS; BERBERINE ALKALOIDS; BIOLOGICAL PRODUCTS; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; OOCYTES; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; XENOPUS LAEVIS;

EID: 84903288898     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0034-1368590     Document Type: Article

References (29)

1. Laverty H. G., Benson C., Cartwright E. J., Cross M. J., Garland C., Hammond T., Holloway C., McMahon N., Milligan J., Park B. K., Pirmohamed M., Pollard C., Radford J., Roome N., Sager P., Singh S., Suter T., Suter W., Trafford A., Volders P. GA, Wallis R., Weaver R., York M., Valentin J. P. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol: 2011; 163 675 693
2. + channels: Structure, function, and clinical significance. Physiol Rev: 2012; 92 1393 1478
3. Kaczorowski G. J., Garcia M. L., Bode J., Hess S. D., Patel U. A. The importance of being profiled: Improving drug candidate safety and efficacy using ion channel profiling. Front Pharmacol: 2011; 2 78
4. Li G. R., Wang H. B., Qin G. W., Jin M. W., Tang Q., Sun H. Y., Du X. L., Deng X. L., Zhang X. H., Chen J. B., Chen L., Xu X. H., Cheng L. C., Chiu S. W., Tse H. F., Vanhoutte P. M., Lau C. P. Acacetin, a natural flavone, selectively inhibits human atrial repolarization potassium currents and prevents atrial fibrillation in dogs. Circulation: 2008; 117 2449 2457
5. Zitron E., Scholz E., Owen R. W., Lück S., Kiesecker C., Thomas D., Kathöfer S., Niroomand F., Kiehn J., Kreye V. AW, Katus H. A., Schoels W., Karle C. A. QTc prolongation by grapefruit juice and its potential pharmacological basis: hERG channel blockade by flavonoids. Circulation: 2005; 111 835 838
6. Liu Y., Xu X. H., Liu Z., Du X. L., Chen K. H., Xin X., Jin Z. D., Shen J. Z., Hu Y., Li G. R., Jin M. W. Effects of the natural flavone trimethylapigenin on cardiac potassium currents. Biochem Pharmacol: 2012; 84 498 506
7. + channels by changrolin in stably transfected HEK293 cells. Acta Pharmacol Sin: 2010; 31 915 922
8. Zhao J., Lian Y., Lu C. F., Jing L., Yuan H. T., Peng S. Q. Inhibitory effects of a bisbenzylisoquinline alkaloid dauricine on hERG potassium channels. J Ethnopharmacol: 2012; 141 685 691
9. Jeong I., Choi B. H., Hahn S. J. Effects of lobeline, a nicotinic receptor ligand, on the cloned Kv1.5. Pflugers Arch: 2010; 460 851 862
10. Schramm A., Baburin I., Hering S., Hamburger M. hERG channel inhibitors in extracts of Coptidis rhizoma. Planta Med: 2011; 77 692 697
11. Schramm A., Jähne E. A., Baburin I., Hering S., Hamburger M. Natural products as potential hERG channel inhibitors: Outcomes from a screening of widely used herbal medicines and edible plants. Planta Med in press
12. A receptor modulation by piperine and a non-TRPV1 activating derivative. Biochem Pharmacol: 2013; 85 1827 1836
13. Kim Y. J., Hong H. K., Lee H. S., Moh S. H., Park J. C., Jo S. H., Choe H. Papaverine, a vasodilator, blocks the pore of the hERG channel at submicromolar concentration. J Cardiovasc Pharmacol: 2008; 52 485 493
14. Kim C. S., Lee N., Son S. J., Lee K. S., Kim H. S., Kwak Y. G., Chae S. W., Lee S., Jeon B. H., Park J. B. Inhibitory effects of coronary vasodilator papaverine on heterologously-expressed hERG currents in Xenopus oocytes. Acta Pharmacol Sin: 2007; 28 503 510
15. Wible B. A., Hawryluk P., Ficker E., Kuryshev Y. A., Kirsch G., Brown A. M. HERG-Lite®: A novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods: 2005; 52 136 145
16. + channels expressed in mammalian cell lines and Xenopus oocytes. J Pharmacol Toxicol Methods: 2002; 48 65 80
17. Xia M. H., Shahane S. A., Huang R. L., Titus S. A., Shum E., Zhao Y., Southall N., Zheng W., Witt K. L., Tice R. R., Austin C. P. Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels. Toxicol Appl Pharmacol: 2011; 252 250 258
18. Vigneault P., Bourgault S., Kaddar N., Caillier B., Pilote S., Patoine D., Simard C., Drolet B. Galantamine (Reminyl®) delays cardiac ventricular repolarization and prolongs the QT interval by blocking the hERG current. Eur J Pharmacol: 2012; 681 68 74
19. Stork D., Timin E. N., Berjukow S., Huber C., Hohaus A., Auer M., Hering S. State dependent dissociation of hERG channel inhibitors. Br J Pharmacol: 2007; 151 1368 1376
20. Rolland A., Fleurentin J., Lanhers M. C., Younos C., Misslin R., Mortier F., Pelt J. M. Behavioural effects of the American traditional plant Eschscholzia californica: Sedative and anxiolytic properties. Planta Med: 1991; 57 212 216
21. Song L. S., Ren G. J., Chen Z. L., Chen Z. H., Zhou Z. N., Cheng H. P. Electrophysiological effects of protopine in cardiac myocytes: Inhibition of multiple cation channel currents. Br J Pharmacol: 2000; 129 893 900
22. Grabher P., Durieu E., Kouloura E., Halabalaki M., Skaltsounis L. A., Meijer L., Hamburger M., Potterat O. Library-based discovery of DYRK1A/CLK1 inhibitors from natural product extracts. Planta Med: 2012; 78 951 956
23. Cahlíková L., Macáková K., Kuneš J., Kurfürst M., Opletal L., Cvačka J., Chlebek J., Blunden G. Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from Eschscholzia californica (Papaveraceae). Nat Prod Commun: 2010; 5 1035 1038
24. Chlebek J., Macáková K., Cahlíková L., Kurfürst M., Kuneš J., Opletal L. Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from Corydalis cava (Fumariaceae). Nat Prod Commun: 2011; 6 607 610
25. Kulhánková A., Cahlíková L., Novák Z., Macáková K., Kuneš J., Opletal L. Alkaloids from Zephyranthes robusta BAKER and their acetylcholinesterase- and butyrylcholinesterase-inhibitory activity. Chem Biodivers: 2013; 10 1120 1127
26. Hoessel R., Leclerc S., Endicott J. A., Nobel M. EM, Lawrie A., Tunnah P., Leost M., Damiens E., Marie D., Marko D., Niederberger E., Tang W., Eisenbrand G., Meijer L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol: 1999; 1 60 67
27. Friedländer P., Roschdestwensky N. Über ein Oxidationsprodukt des Indigoblaus. Ber Dtsch Chem Ges: 1915; 48 1841 1847
28. Dostál J., Potáček M., Man S., Humpa O. Non-aromatic derivatives of berberine. Scr Med (Brno): 1999; 72 3 8
29. Baburin I., Beyl S., Hering S. Automated fast perfusion of Xenopus oocytes for drug screening. Pflugers Arch: 2006; 453 117 123